The complete article can be found at AlabamaNewsCenter.com.
By Jeff Hansen
Use of the diabetes drug metformin – before a diagnosis of COVID-19 – is associated with a threefold decrease in mortality in COVID-19 patients with Type 2 diabetes, according to a racially diverse study at UAB. Diabetes is a significant comorbidity for COVID-19.
“This beneficial effect remained, even after correcting for age, sex, race, obesity and hypertension or chronic kidney disease and heart failure,” said Dr. Anath Shalev, director of UAB’s Comprehensive Diabetes Center and leader of the study.
“Since similar results have now been obtained in different populations from around the world – including China, France and a UnitedHealthcare analysis – this suggests that the observed reduction in mortality risk associated with metformin use in subjects with Type 2 diabetes and COVID-19 might be generalizable,” Shalev said.
Click HERE to see the full article on the Alabama NewsCenter website.